ManRider
Bluelighter
- Joined
- Apr 18, 2008
- Messages
- 78
I was poking around google scholar trying to learn about MDMA and its relationship to oxytocin release when I found this interesting little article:
http://linkinghub.elsevier.com/retrieve/pii/S0306452207001960
The test subjects are just rats of course, but they observe increased social interaction after MDMA administration and then a similar increase in social interation after the administration of another oxytocin releaser, 8-HO-DAPT. The article suggests that for these compounds 5-HT1a agonism is the route to oxytocin release.
This got me thinking about this compound and other similar ones being used as social drugs, both recreationally and for utility to deal with shyness, etc. Does anyone know of this kind of thing being done, or perhaps have thoughts to share on the matter?
Here's the abstract from the article if you don't want to go to the link
http://linkinghub.elsevier.com/retrieve/pii/S0306452207001960
The test subjects are just rats of course, but they observe increased social interaction after MDMA administration and then a similar increase in social interation after the administration of another oxytocin releaser, 8-HO-DAPT. The article suggests that for these compounds 5-HT1a agonism is the route to oxytocin release.
This got me thinking about this compound and other similar ones being used as social drugs, both recreationally and for utility to deal with shyness, etc. Does anyone know of this kind of thing being done, or perhaps have thoughts to share on the matter?
Here's the abstract from the article if you don't want to go to the link
The drug 3,4 methylenedioxymethamphetamine (MDMA; ecstasy) has a widely documented ability to increase feelings of love and closeness toward others. The present study investigated whether oxytocin, a neuropeptide involved in affiliative behavior, may play a role in this effect. A moderate (5 mg/kg, i.p.) dose of MDMA increased social interaction in male Wistar rats, primarily by increasing the amount of time rats spent lying adjacent to each other. MDMA (5 mg/kg) activated oxytocin-containing neurons in the supraoptic and paraventricular nuclei of the hypothalamus, as shown by Fos immunohistochemistry. MDMA (5 mg/kg i.p.) also increased plasma oxytocin levels and this effect was prevented by pre-treatment with the 5-HT1A antagonist N-[2-[4-(2-methyoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide maleate salt (WAY 100,635; 1 mg/kg i.p.). The oxytocin receptor antagonist tocinoic acid (20 μg, i.c.v.) had no effect on social behavior when given alone but significantly attenuated the facilitation of social interaction produced by MDMA (5 mg/kg). The 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)-tetraline) (8-OH-DPAT, 0.25 mg/kg, i.p.) increased social behavior in a similar way to MDMA and this effect was also significantly attenuated by tocinoic acid. Taken together, these results suggest that oxytocin release, stimulated by MDMA through 5-HT1A receptors, may play a key role in the prosocial effects of MDMA and underlie some of the reinforcing effects of the drug.